CTSI’s Research Team Building Consultation Service

Sponsor:

NYU Langone Medical Center’s Clinical and Translation Science Institute

Deadline:

Rolling, but space is limited.

Summary:

The Research Team Building Consultation Service, funded through NYULMC’s CTSI mentoring program, was designed to help investigators at various stages (post docs through more senior investigators) build or enhance their team to improve research productivity while providing mentoring and training to the next generation of scholars, particularly those underrepresented in science. We help faculty/post docs build labs, design teams, and recruit over a 12-month period.

Eligibility:

No additional eligibility restrictions.

Available Funding:

Not applicable. The service will provide 15 hours of individual consultation for each investigator.

Link to Full RFP:

CTSI July 2017 Newsletter

MSK Lymphoma SPORE 2017-2018 Career Enhancement Program (CEP) Awards

Sponsor:
Hosted at Memorial Sloan Kettering Cancer Center – Funded by the National Institutes of Health

Deadline:

July 28, 2017

Summary:

The aim of this RFA is to identify, train and/or develop talented individuals to become successful translational investigators in the field of lymphoma. The program will support 1 or 2 individuals per year for up to two years per awardee, based on competitive renewal. Awardees will be integrated into the SPORE in order to monitor their progress and ensure successful outcome of their research projects, and will be prepared to obtain independent peer-reviewed funding.

Eligibility:

Investigators at Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical Center, Columbia University, Mount Sinai Hospital, and NYU, are eligible.
Funds from this program may be used to support junior faculty or established investigators who wish to enhance or refocus their careers on translational research. Eligible candidates will include individuals with the following qualifications:
a) M.D. (or D.O), PhD, or MD/PhD degree. This program is not a training program and does not support pre- or post-doctoral fellows, either pre-clinical or clinical. However, advanced post-doctoral or clinical fellows who provide a letter from an institution stating that the candidate will be joining its faculty within the year are eligible for this program.
b) Commitment to a career path in translational lymphoma research. Candidates must have demonstrated a strong aptitude for and interest in biomedical research, as evidenced by experience in the laboratory or other relevant research.
c) Exceptional clinical candidates that do not currently have an active laboratory program may also apply, provided they have a strong scientific/laboratory background, and are working with a laboratory mentor who can provide them with the necessary guidance and resources to develop a hypothesis that can be tested in the clinical setting
d) Investigators supported by NCI career development awards (K series) may also be eligible for support through this program. Investigators with previous R01 or equivalent level of funding related to lymphoma translational research are not eligible

Anticipated Funding Amount:

The program will support 1 or 2 individuals per year for up to two years per awardee, based on competitive renewal. The maximum award will be $50,000 for one year. Applicants will be funded for a maximum of two years with funding for the second year contingent on documented significant progress during the first year of funding, and peer review evaluations.

PROPOSAL PROCESS:

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs). Proposals must be submitted to Felicia Reid reidf@mskcc.org by July 24th, 2017.

REQUIRED INFORMATION:

Research proposals must be no longer than 5 pages (excluding budget) and should follow the format for an R01 grant application; the length of the final proposal are limited to 6 pages. The proposals will require the following standard NIH format:
Format: Applications must be in 11-point Arial. Margins must be at least 0.50 inches wide on all sides of each page.
1) Face Page (including Title, Name of Applicant, and Names of Key Collaborators)
2) Abstract (250 words max)
3) Research Plan (5-page limit). Include the following content: Specific Aims, Preliminary Studies, and Research Strategy (a. Significance, b. Innovation, c. Approach)
4) Research environment (1 page)
5) Include up to 6 Literature Citations
6) Human Subjects or Vertebrate Animals. (Please follow the NIH guidelines)
7) NIH Biosketch for all key personnel (5 pages each in NIH-specified format)
8) Budget and Budget Justification. Include a detailed NIH-format Budget for one year totaling $50,000 direct costs. The application must include a detailed budget for the initial year, a summary budget, and a budget justification.
9) The application should include a statement of long-term career goals, letter of support from the mentor with the Mentor’s CV, and 3 letters of recommendation.
REVIEW CRITERIA:
Applications will be reviewed and scored by the CEP Committee, which is composed of a diverse pool of experienced individuals with laboratory and clinical expertise. The CEP Co-Directors will assign two reviewers from the CEP Committee (one primary and one secondary reviewer) for each proposal. The initial selection will be based on the following criteria:
1. Scientific merit of the proposed project
2. Innovation
3. Approach
4. Qualifications of the investigator
5. Qualifications of the mentor
6. Research environment
IRB approval (or waiver) will be required before funding if the study involves human subjects.
SCIENTIFIC REVIEW COMMITTEE:
The CEP Co-Directors will assign two reviewers from the CEP Committee (one primary and one secondary reviewer) for each proposal.
FUNDING CYCLES:
Awards will begin in August 2017
Authors must cite the MSK Lymphoma SPORE (P50 CA192937) in the funding acknowledgements when submitting a manuscript based on research supported, in whole or in part, by this SPORE-Career Enhancement Program.
Written progress and final reports will be required at the end of funding period. Any questions regarding this solicitation should be directed to Felicia Reid reidf@mskcc.org or to the CEP directors; Dr. Riccardo Dalla Favera rd10@cumc.columbia.edu or Dr. Andrew Zelenetz Zelenetz a-zelenetz@ski.mskcc.org.
KEY DATES:
• Applications are due on July 24th, 2017
• Award Announcements by August 18th, 2017
• Award Start Date: August 30th, 2017
SUBMISSION INFORMATION:
Proposals must be submitted electronically to Felicia Reid reidf@mskcc.org. Proposals must be submitted as a compiled PDF document.
ADDITIONAL BUDGET INFORMATION:
Up to $50K direct costs for one year, may be renewable for an additional year based on review
Expenditures allowed
1 Research supplies and animal maintenance.
2 Technical assistance.
3 Publication costs, including reprints.
4 Data analysis.
5 Special fees (pathology, photography, etc.).
6 Stipends for graduate students and postdoctoral fellows.
The following expenditures will not be considered:
1 Secretary or administrative personnel.
2 Office equipment or supplies.
3 Laboratory equipment or computers.
4 Tuition.
5 Foreign travel.
6 Honoraria and travel expenditures.
7 Recruitment.
8 Patient care charges (requires justification if a clinical trial is proposed).
9 Non-medical or personal services to patients

 

MSK Lymphoma SPORE 2017-2018 Developmental Research Program (DRP) Awards

Sponsor:
Hosted at Memorial Sloan Kettering Cancer Center – Funded by the National Institutes of Health

Deadline:

July 28, 2017

Summary:

This RFA is designed to support young investigators as well as established investigators focusing on basic, translational, or clinical research of lymphoma. The primary objective of this DRP Award is to support pilot projects that explore innovative ideas in basic and translational research in lymphoma. Potential topics of interest include, but are not limited to:
• Pathogenesis
• Experimental therapeutics, including mechanism based combinations, and biomarker driven treatment strategies
• Immunology and immunotherapies
• Circulating tumor DNA

Eligibility:

Investigators at Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medical Center, Columbia University, Mount Sinai Hospital, and NYU, are eligible.
Applicants must hold academic rank of Instructor, Assistant Professor, or higher.
Applicants must possess an MD, DO or a PhD degree in a relevant area of research. The pilot projects may be collaborative among scientists within one or more SPOREs, or with scientists outside the SPORE community including the international scientific community. High risk/high payoff pilot projects are especially encouraged. These pilot projects do not need to reach a human endpoint during the project period as do full projects, including the Developmental Research Program. Letters of collaboration (if if applicable)

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs).

Anticipated Funding Amount:

Each year, 3-4 applications will be funded. The maximum award will be $50,000 for one year. Applicants will be funded for a maximum of two years with funding for the second year contingent on documented significant progress during the first year of funding, and peer review evaluations.

PROPOSAL PROCESS:

Proposals cannot be currently funded by an extramural agency or foundation. The budget is limited to $50K/year (direct costs. No indirect costs). Proposals must be submitted to Felicia Reid reidf@mskcc.org by July 24th, 2017.

REQUIRED INFORMATION:
Research proposals must be no longer than 5 pages (excluding budget) and should follow the format for an R01 grant application; the length of the final proposal are limited to 6 pages. The proposals will require the following standard NIH format:
Format: Applications must be in 11-point Arial. Margins must be at least 0.50 inches wide on all sides of each page.
MSK Lymphoma SPORE
2017-2018 Developmental Research Program (DRP) Awards
1) Face Page (including Title, Name of Applicant, and Names of Key Collaborators)
2) Abstract (250 words max)
3) Research Plan (5-page limit). Include the following content: Specific Aims, Preliminary Studies, and Research Strategy (a. Significance, b. Innovation, c. Approach)
6) Research environment (1 page)
7) Include up to 6 Literature Citations
8) Human Subjects or Vertebrate Animals. (Please follow the NIH guidelines)
9) NIH Biosketch for all key personnel (5 pages each in NIH-specified format)
10) Budget and Budget Justification. Include a detailed NIH-format Budget for one year totaling $50,000 direct costs. The application must include a detailed budget for the initial year, a summary budget, and a budget justification.
REVIEW CRITERIA:
All proposals will be reviewed by the scientific review committee and ad hoc reviewers, according to the following criteria, as relevant:
1. Scientific merit of the proposed project
2. Innovation
3. Approach
4. Qualifications of the investigator
5. Research environment
IRB approval (or waiver) will be required before funding if the study involves human subjects.
SCIENTIFIC REVIEW COMMITTEE:
The DRP Review Committee will include 3 ad hoc members of the SPORE Internal Advisory Board Committee, and 3 ad hoc members of the SPORE External Advisory Board Committee, and 3 additional external reviewers from other lymphoma SPORES
FUNDING CYCLES:
Awards will begin in August 2017
Authors must cite the MSK Lymphoma SPORE (P50 CA192937) in the funding acknowledgements when submitting a manuscript based on research supported, in whole or in part, by this SPORE-Developmental Research Program.
Written progress and final reports will be required at the end of funding period. Any questions regarding this solicitation should be directed to Felicia Reid reidf@mskcc.org or to the DRP directors; Dr. John Leonard jpleonar@med.cornell.edu or Dr. Anas Younes younesa@mskcc.org.
KEY DATES:
• Applications are due on July 24th, 2017
• Award Announcements by August 18th, 2017
• Award Start Date: August 30th, 2017

SUBMISSION INFORMATION:
Proposals must be submitted electronically to Felicia Reid reidf@mskcc.org. Proposals must be submitted as a compiled PDF document.
ADDITIONAL BUDGET INFORMATION: Up to $50K direct costs for one year, may be renewable for an additional year based on review
Expenditures allowed
1 Research supplies and animal maintenance.
2 Technical assistance.
3 Publication costs, including reprints.
4 Data analysis.
5 Special fees (pathology, photography, etc.).
6 Stipends for graduate students and postdoctoral fellows.
The following expenditures will not be considered:
1 Secretary or administrative personnel.
2 Office equipment or supplies.
3 Laboratory equipment or computers.
4 Tuition.
5 Foreign travel.
6 Honoraria and travel expenditures.
7 Recruitment.
8 Patient care charges (requires justification if a clinical trial is proposed).
9 Non-medical or personal services to patients.

Bone Marrow Failure Research Program Idea Development Award

Sponsor:

U.S. Department of Defense

Deadline:

Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), March 29, 2016

Application Submission Deadline: 11:59 p.m. ET, July 13, 2016

Summary:

The vision of the BMFRP is to understand and cure BMF syndromes. Toward that end, the program challenges the scientific community to design innovative research approaches based on sound scientific evidence that will advance the understanding of inherited and acquired BMF syndromes to improve the health of individuals, with the ultimate goals of prevention and cure.

The FY16 BMFRP objective is to fund scientifically meritorious research focused on BMF syndromes. Investigator‐initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF syndromes and their progression to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies and translational projects including bone marrow transplantation studies should be clearly related to BMF syndromes.

Eligibility:

Investigators at or above the level of Associate Professor (or equivalent) are eligible to apply as EIs.

Eligible investigators must apply through an organization. Organizations eligible to apply include Federal agencies, national, international, for-profit, nonprofit, public, and private organizations.

Available Funding:

The maximum period of performance is 2 years.

The anticipated direct costs budgeted for the entire period of performance will not exceed $315,000. Indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $315,000 direct costs or using an indirect rate exceeding the organization’s negotiated rate.

Link to Full RFP:

http://cdmrp.army.mil/funding/pa/16bmfrpida_pa.pdf

Independent Grants for Learning & Change (IGLC) – Acute Lymphoblastic Leukemia (ALL)

Sponsor:

Pfizer

Deadline:

Applications due February 23, 2016 by 11:59 PM Eastern

Summary:

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly. Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need.

It is our intent to support projects that focus on increasing the awareness and understanding of novel therapies, including AntibodyDrug Conjugates (ADCs), as new treatment options for patients with relapsed refractory Acute Lymphoblastic Leukemia (ALL). Target learner audiences include: hematologists, medical oncologists, transplant specialists, nurses, and any healthcare professionals involved in the care or treatment of ALL patients.

All activity types will be considered through this CGA including live events, satellite symposia, workshops, online courses, print materials, other enduring materials. An activity taking place alongside the American Society of Hematology (ASH) conference in December 2016 is of particular interest. High levels of interactivity are encouraged in order to facilitate learning. Proposals may include scientific course content on topics such as ADC mechanisms of action. Areas of special interest include practical education, patient case discussions, and clinical practice tools that address such questions as when and how to use these targeted therapies, how to anticipate and manage side effects, etc.

Eligibility:

The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

Available Funding:

Grant applications requesting up to $750,000 will be considered.

The total available budget for this CGA is $750,000.

Link to Full RFP:

http://www.pfizer.com/files/IGLC_CGA16ON1_AcuteLymphoblasticLeukemia.pdf

Centers of Research Excellence in Science and Technology (CREST) and HBCU Research Infrastructure for Science and Engineering (RISE)- NSF 16-525

Sponsor:

National Science Foundation

Deadline:

Letter of Intent Due Date(s) (required) (due by 5 p.m. proposer’s local time):

March 04, 2016

Letters of Intent are due for preliminary CREST Center proposals.

April 07, 2016

Letters of Intent are due for HBCU-RISE projects.

December 02, 2016

Letters of Intent are due for HBCU-RISE projects.

Preliminary Proposal Due Date(s) (required) (due by 5 p.m. proposer’s local time) :

June 10, 2016

Preliminary proposals are due for CREST Centers.

Supplement Due Date(s) (due by 5 p.m. proposer’s local time):

Proposals Accepted Anytime

SBIR/STTR Diversity Collaborative Supplements

June 13, 2016

Proposals are due for CREST Partnership Supplements.

February 13, 2017

Proposals are due for CREST Partnership Supplements.

Full Proposal Deadline(s) (due by 5 p.m. proposer’s local time):

June 10, 2016

Proposals are due for HBCU-RISE.

December 02, 2016

First Friday in December, Annually Thereafter

Proposals are due for CREST Postdoctoral Research Fellowships.

February 10, 2017

Full proposals are due for CREST Centers and HBCU-RISE.

Summary:

The Centers of Research Excellence in Science and Technology (CREST) program provides support to enhance the research capabilities of minority-serving institutions (MSI) through the establishment of centers that effectively integrate education and research. MSIs of higher education denote institutions that have undergraduate enrollments of 50% or more (based on total student enrollment) of members of minority groups underrepresented among those holding advanced degrees in science and engineering fields: African Americans, Alaska Natives, American Indians, Hispanic Americans, Native Hawaiians, and Native Pacific Islanders. CREST promotes the development of new knowledge, enhancements of the research productivity of individual faculty, and an expanded presence of students historically underrepresented in science, technology, engineering, and mathematics (STEM) disciplines. CREST Postdoctoral Research Fellowship (PRF) awards provide research experience and training for early career scientists to work at active CREST Centers to meet the CREST Program goal of building the research capacity of MSIs and advancing the nation’s STEM workforce and leadership. HBCU-RISE awards specifically target HBCUs to support the expansion of institutional research capacity as well as the production of doctoral students, especially those from groups underrepresented in STEM, at those institutions.

The CREST program supports the following types of projects:

CREST Center awards provide multi-year support (typically 5-years) for eligible minority-serving institutions that demonstrate a strong research and education base, a compelling vision for research infrastructure improvement, and a comprehensive plan with the necessary elements to achieve and sustain national competitiveness in a clearly defined area of national significance in science or engineering research. Successful Center proposals will demonstrate a clear vision and synergy with the broad goals of the CREST Program and the Human Resource Development Division with respect to development of a diverse STEM workforce. CREST Centers are expected to provide leadership in the involvement of groups traditionally underrepresented in STEM at all levels (faculty, students, and postdoctoral researchers) within the Center. Centers are required to use either proven or innovative mechanisms to address issues such as recruitment, retention and mentorship of participants from underrepresented groups.

CREST Partnership Supplements support the establishment or strengthening of partnerships and collaborations between active CREST Centers and nationally or internationally recognized research centers including NSF-supported research centers, and private sector research laboratories, K-12 entities including museums and science centers or schools, as appropriate to enable the CREST Centers to advance knowledge and education on a research theme of national significance.

CREST Postdoctoral Research Fellowship (PRF) awards recognize beginning CREST Center investigators with significant potential and provide them with research experiences that broaden perspectives, facilitate interdisciplinary interactions and establish them in positions of leadership within the scientific community. Fellows conduct research on topics aligned with the research focus of the host CREST Center. The fellowships are also designed to provide active mentoring to the Fellows by the sponsoring CREST Center scientists who, in turn, will benefit from the incorporation of these talented scientists into their research groups.

HBCU Research Infrastructure for Science and Engineering (RISE) awards support the development of research capability at Historically Black Colleges and Universities that offer doctoral degrees in science and engineering disciplines. Supported projects must have a unifying research focus in one of the research areas supported by NSF, a direct connection to the long-term plans of the host department(s), institutional strategic plan and mission, and plans for expanding institutional research capacity as well as increasing the production of doctoral students, especially those underrepresented in STEM.

SBIR/STTR Phase IIa Diversity Collaboration Supplements provide an opportunity for existing SBIR/STTR Phase II projects to initiate collaborations with minority-serving institutions that have active CREST Center or HBCU-RISE awards. These supplemental proposals are administered by and co-funded with the NSF Directorate for Engineering Division of Industrial Innovation and Partnerships (ENG/IIP).

 

Eligibility:             

Only one preliminary CREST Center proposal may be submitted per eligible institution. Full CREST Center proposals are to be submitted only when invited by NSF. An institution may have only one active CREST Center award, irrespective of focus area. Centers that have completed two prior, consecutive 5-year CREST Center awards may recompete in disciplinary areas that are significantly different from those of the previous award(s).

Only two (2) individuals per active CREST Center may submit a CREST-PRF application per competition. Only one individual can be awarded a CREST-PRF at an active CREST Center per year.

Only one HBCU-RISE proposal may be submitted per eligible institution. An institution may have only one active HBCU-RISE award.

For each active SBIR/STTR Phase II grant, only one SBIR/STTR collaboration with a CREST Center may be submitted. For each CREST center, only one SBIR/STTR collaboration can be active at any given time.

 

Eligible individuals may be listed as the principal investigator or co-principal investigator on only one CREST Center or HBCU-RISE proposal. CREST-PRF applicants may submit only one fellowship application to the CREST program per year and may apply in no more than two successive years for CREST-PRF.

See full RFP for detailed requirements for eligibility.

Available Funding:

Estimated Number of Awards: 46

In fiscal year 2016, up to 4 SBIR/STTR Diversity Collaborative Supplements, up to 7 CREST Partnership Supplements and up to 4 HBCU-RISE awards will be made. In fiscal year 2017, up to 6 CREST Center awards (new Centers and Phase II competitive renewals), up to 10 CREST-PRFs, up to 4 SBIR/STTR Diversity Collaborative Supplements, up to 7 CREST Partnership Supplements and up to 4 HBCU-RISE awards will be made.

Anticipated Funding Amount: $17,800,000

Across fiscal years 2016 and 2017, up to $6,000,000 to support the first year for six newly funded CREST Centers, up to $1,200,000 for CREST-PRF standard grants, up to $600,000 from CREST and $600,000 from ENG/IIP for co-funded SBIR/STTR Diversity Collaborative Supplements, up to $1,400,000 for CREST partnership supplements and up to $8,000,000 for HBCU-RISE standard grants, pending the availability of funds.

Link to Full RFP:

http://www.nsf.gov/pubs/2016/nsf16525/nsf16525.htm?WT.mc_id=USNSF_25&WT.mc_ev=click

TREC POST-DOCTORAL TRAINING SUPPORT PROGRAM IN CLINICAL AND TRANSLATIONAL RESEARCH (TL1)

 Sponsor:

The Clinical and Translational Science Institute (CTSI) of New York University and NYC Health and Hospitals Corporation

Deadline:

February 10, 2016 at 5pm.

Summary:
The Clinical and Translational Science Institute (CTSI) of New York University and NYC Health and Hospitals Corporation is pleased to announce the availability of a funding/training program opportunity for one early-stage post-doctoral scholar conducting research in the area of health care and/or translational medicine. We particularly encourage applications from historically underrepresented racial and ethnic groups in the area of healthcare and translational medicine. We have a commitment to diversity and inclusion.

The fundamental goal of the program is to help and support the scholar as s/he advances in her/his research career, and to provide them with the knowledge and skills to eventually develop into successful, independent researchers. The scholar will join three other post-doctoral scholars already in the program. The program encourages productivity, collaborative research and career development.

Clinical and translational science is the term for multidisciplinary, team-based research that has the goal of transforming basic science discoveries to improve human health through new diagnostic techniques, new therapies, advances in clinical practice and new community-based interventions or population health initiatives.

Eligibility:

Early stage post-doctoral research scholars (1-2 years after completion of pre-doctoral training) are eligible to apply. Post-doctoral scholars should be actively engaged in clinical or translational research. Scholars from any unit or school in the University, or with appointments at CTSI-affiliated New York City Health and Hospitals Corporation institutions, are eligible to apply. Applicants must have the support of their research advisor/mentor.

Available Funding:

The program will provide salary, training and mentoring while emphasizing the scholar’s success within their established research area.

 Link to Full RFP:

http://www.med.nyu.edu/ctsi/training-education/research-career-development/tl1

AACR- Career Development Award for Metastatic Triple Negative Breast Cancer Research

Sponsor:

American Association for Cancer Research

Deadline:

Applications are due January 19, 2016 at 12:00 PM Eastern

Summary:

The AACR-Triple Negative Breast Cancer Foundation-Carol’s Crusade for a Cure Foundation Career Development Award for Metastatic Triple Negative Breast Cancer Research represents a joint effort to encourage and support junior faculty to conduct metastatic triple negative breast cancer research and establish a successful career path in this field. The research proposed for funding may be basic, translational, or clinical in nature and must have direct applicability and relevance to metastatic triple negative breast cancer.

This grant, supported by the Triple Negative Breast Cancer Foundation and Carol’s Crusade for a Cure Foundation, established in memory of Carol Eilbott Klebanow, provides $250,000 over three years ($83,333 per year) for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students and/or research assistants, research/laboratory supplies, equipment, travel, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

The AACR-Triple Negative Breast Cancer Foundation-Carol’s Crusade for a Cure Foundation Career Development Award for Metastatic Triple Negative Breast Cancer Research is being awarded in honor of Carol Eilbott Klebanow.

​Research projects may be basic, translational, or clinical in nature and must have direct applicability and relevance to metastatic triple negative breast cancer.

Eligibility:

​At the start of the grant term on July 1, 2016, applicants must hold a full-time, faculty position with the title of assistant professor, instructor, research assistant professor, or the equivalent; have completed his or her most recent doctoral degree within the past 11 years (i.e., degree cannot have been conferred before July 2, 2005); have independent laboratory space as confirmed by your institution; and work at an academic, medical, or research institution anywhere in the world.

Applicants with a medical degree must have completed his or her most recent doctoral degree or medical residency – whichever date is later – within the past 11 years (time spent in medical specialty or subspecialty training is not considered part of medical residency and will be counted against the 11 year window).

Applicants must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent doctoral degree) in a related field and not currently be a candidate for a further doctoral or professional degree.

Employees or subcontractors of a U.S. government entity or for-profit private industry are not eligible.

Any individual who currently holds an active AACR grant may not apply. Past grantees may apply if they complied with all progress and financial report requirements.

Investigators may submit only one application for the AACR-Triple Negative Breast Cancer Foundation-Carol’s Crusade for a Cure Foundation Career Development Award for Metastatic Triple Negative Breast Cancer Research but may concurrently apply for other AACR grants. However, applicants are expected to accept the first grant they are awarded. Individuals may accept and hold only one AACR grant at a time.

Postdoctoral or clinical research fellows or the equivalent who are working under the auspices of a scientific mentor are not eligible to apply. Qualified fellows are invited to apply for an AACR Fellowship.

​AACR membership is required. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active Membership by Tuesday, January 19, 2016. 

Available Funding:

One (1) three-year grant in the amount of $250,000.

Link to Full RFP:

http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=46#.VpUwZrYrJaQ

AACR-Bayer Innovation and Discovery Grants

Sponsor:

American Association for Cancer Research

Deadline:

Applications are due January 19, 2016 at 12:00 PM Eastern

Summary:

Bayer and the AACR are proud to announce the 2016 AACR-Bayer Innovation and Discovery Grants.

This new grants partnership will promote the key tenets of the Bayer Grants4Targets™ Initiative, providing new treatment options for cancers with high unmet medical need, encouraging innovation and translation of ideas from basic research into novel drugs, and fostering collaborations between excellent academic groups and the pharmaceutical industry. This program offers one-year grants of $10,000-$25,000 to meritorious projects that examine important, and druggable*, novel targets and biomarkers.

It is anticipated that multiple grants will be funded.

*For the purposes of this grant program, a “druggable” target is defined as a nucleic acid or a protein (e.g., an enzyme, a receptor) whose activity can be modified by a drug. The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in cancer by relevant in vitro or in vivo models. A cancer-related biomarker might be a protein, a nucleic acid, or a metabolite that can be measured in biological fluids, tissue, or isolated cells for the diagnosis, monitoring, prognosis, or stratification of patients.

​Successful applications will focus on the following oncology research areas:

  • Inhibition of cell proliferation
  • Survival signaling
  • Transcription and chromatin modulation
  • Cell cycle regulation
  • Tumor metabolism
  • Hypoxia
  • Immunotherapy
  • Antibody-drug conjugates

Applications that propose research outside of these areas (e.g., gene or cell therapy, vaccination, or unspecified approaches without defined molecular targets) will not be considered for review.

Eligibility:

In order to be eligible for this opportunity, applicants must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent doctoral degree) in a related field and not currently be a candidate for a further doctoral or professional degree.

Applications will be accepted from independent investigators at all levels who are affiliated with an academic, medical or research institution in North America. Employees or subcontractors of a U.S. government entity or for-profit private industry are not eligible.

Investigators may submit only one application for an AACR-Bayer Innovation and Discovery Grant but may concurrently apply for other AACR grants.

Members of the Scientific Review Committee are not eligible to apply for an AACR-Bayer Innovation and Discovery Grant.

​AACR membership is required. Nonmembers interested in this grant opportunity must submit a satisfactory application for AACR Active Membership by Tuesday, January 19, 2016.

Available Funding:

This program offers one-year grants of $10,000-$25,000.

Link to Full RFP:

http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=53#.VpUs9bYrJaQ

NIH Transformative Research Awards (R01)- RFA-RM-15-005

Sponsor:

National Institutes of Health

Deadline:

Letter of Intent Due Date(s)

September 9, 2015

Application Due Date(s)

October 9, 2015, by 5:00 PM

Summary:

The NIH Transformative Research Awards complement NIH’s traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad area of biomedical or behavioral research.

Eligibility:

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Available Funding:

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Link to Full RFP:

http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-005.html